

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/606,711	06/26/2003	Stephen D. Pacetti	50623.266	5769	
7590 04/20/2006			EXAM	EXAMINER	
Victor Repkin			AHMED, SHEEBA		
Squire, Sanders & Dempsey L.L.P. Suite 300			ART UNIT	PAPER NUMBER	
One Maritime Plaza San Francisco, CA 94111			1773		
			DATE MAILED: 04/20/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

0.5		Application No.	Applicant(s)	$\checkmark$		
) Office Action Commence		дрисацоп но.				
		10/606,711	PACETTI, STEPHEN D.			
	Office Action Summary	Examiner	Art Unit			
		Sheeba Ahmed	1773			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Openiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE.	I. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
2a) <u></u> ☐	Responsive to communication(s) filed on This action is <b>FINAL</b> . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Dispositi	ion of Claims					
5)□ 6)⊠ 7)□ 8)□	Claim(s) 1-29 is/are pending in the application.  4a) Of the above claim(s) is/are withdray  Claim(s) is/are allowed.  Claim(s) 1-29 is/are rejected.  Claim(s) is/are objected to.  Claim(s) are subject to restriction and/or	vn from consideration.				
Applicati	on Papers					
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	epted or b) objected to by the Eddrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority u	ınder 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
2) Notice 3) Information	t(s) te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date 7/28/03.	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal P 6)  Other:				

Application/Control Number: 10/606,711

Art Unit: 1773

## **DETAILED ACTION**

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 1. Claims 1-3, 5-8, 12, 13, and 15-18 are rejected under 35 U.S.C. 102(b) as being anticipated by Zhong (US 6,231,600).

Zhong discloses implantable medical devices, such as stents, having a first coating of TAXOL and a polymer and a second coating of heparin bonded to the first coating through a crosslinking agent (Column 1, lines 15-25). Substrates suitable for such coatings include plastics, metals, glass and ceramics (Column 3, lines 18-23). Examples of polymers used in the fist coatings include polymethacrylates and polyacrylates (Column 3, lines 46). All limitations of claims 1-3, 5-8, 12, 13, and 15-18 are disclosed in the above reference.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under

Application/Control Number: 10/606,711

Art Unit: 1773

the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

2. Claims 1-29 are rejected under 35 U.S.C. 102(b) as being anticipated by Hossainy et al. (US 6,926,919 B1).

Hossainy et al. disclose drug eluting vascular stents having a coating including a blend of a hydrophobic and hydrophilic polymer and treating the coating with a stimulus for enriching a region close to the outer surface of the coating with a hydrophilic polymer such that the region of the coating close to the outermost surface of the stent has a higher content of the hydrophilic component than the hydrophobic component (Column 2, lines 12-40). The coating further comprises an optional primer layer and an optional topcoat layer (Column 2, lines 42-60). Poly(ethylene-co-vinyl alcohol) is one example of a hydrophobic component and can be used to fabricate the topcoat or primer layers as well. Other examples include the list given in Columns 3 and 4. All limitations of claims 1-29 are recited in the above reference.

## Conclusion

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheeba Ahmed whose telephone number is (571)272-1504. The examiner can normally be reached on Monday-Friday from 6am to 2pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Carol Chaney can be reached on (571)272-1284. The fax

Art Unit: 1773

phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sheeba Ahmed Art Unit 1773

April 17, 2006